Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma

Journal of Immunotherapy

Volumn 28, Issue 6, 2005, Pages 525-534

  Pop, Laurentiu M ^a   Smallshaw, Joan E ^a   Tucker, Thomas F ^a   Stevenson, Freda K ^b   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Dormancy; Idiotype; Lymphoma; Vaccine

Indexed keywords

ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; IDIOTYPIC ANTIBODY; IDIOTYPIC PROTEIN BCL1; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; KEYHOLE LIMPET HEMOCYANIN; PROTEIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B CELL LYMPHOMA; CANCER RELAPSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IN VIVO STUDY; INOCULATION; MALE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT FAILURE; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; VACCINATION;

EID: 27444445005     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000175493.05852.5a     Document Type: Article

References (62)

1. 1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol. 1986;137:1376-1382.
2. 1. J Immunol. 1987;138: 628-634.
3. 1 lymphoma. Cancer Res. 1991;51:50458-50538.
4. 1 tumor after dormancy is established. Blood. 1997;89:4425-4436.
5. George AJT, Stevenson FK. Prospects for the treatment of B cell tumors using idiotypic vaccination. Int Rev Immunol. 1989;4:271-310.
6. Stevenson FK, George AJ, Glennie MJ. Anti-idiotypic therapy of leukemias and lymphomas. Chem Immunol. 1990;48:126-166.
7. Yefenof E, Picker LJ, Scheuermann RH, et al. Cancer dormancy: Isolation and characterization of dormant lymphoma cells. Proc Natl Acad Sci USA. 1993;90:1829-1833.
8. Racila E, Scheuermann RH, Picker LJ, et al. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med. 1995;181:1539-1550.
9. + T cells and IFN-g in establishing and maintaining the tumor-dormant state. J Immunol. 1999;162:2842-2849.
10. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med. 1998;4:1281-1286.
11. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells by passes T helper function in the generation of an antitumor response. Cell. 1990;60:397-403.
12. Shimizu K, Fields RC, Giedlin M, et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA. 1999;96:2268-2273.
13. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blodkage and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823-832.
14. Gregor PD, Wolchok JD, Ferrone CR, et al. CTLA-4 blockage in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004;22:1700-1708.
15. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res. 1999;59:3128-3133.
16. + regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol. 2004;13:613-620.
17. Brooks K, Yuan D, Uhr JW, et al. Lymphokine-induced IgM secretion by clones of neoplastic B cells. Nature. 1983;302:825-826.
18. 1, a murine model for chronic lymphocytic leukemia: Use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev. 1979;48:81-106.
19. Knapp MR, Jones PP, Black SJ, et al. Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR. J Immunol. 1979;123:992-999.
20. 1). III. Evidence for monoclonality by using an anti-idiotype antibody. J Immunol. 1979;122:1649-1654.
21. Yagawa K, Vitetta ES. Induction of proliferation and differentiation of murine B cells bearing surface Ig lambda by rat monoclonal antibody to lambda chain. Hybridoma. 1983;2:169-175.
22. Holmes K, Lantz LM, Fowlkes BJ, et al. Labeling antibody with fluorescein isothiocyanate. Curr Protocols Immunol. 2003;44:5.3.5.
23. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-446.
24. Callaway MP, Briggs JC. The incidence of later recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg. 1989;42:46-49.
25. Demicheli R. Tumor dormancy and metastasis development inoperable breast cancer: data from clinical trials, in Yefenof E, Scheuermann RH (eds.). Premalignancy and Tumor Dormancy. 1996:181-191.
26. Sagalowsky AI, Molberg K. Solitary metastasis of renal cell carcinoma to the contralateral adrenal gland 22 years after nephrectomy. Urology. 1999; 54:162-165.
27. Uhr JW, Marches R. Dormancy in a model of murine B cell lymphoma. Cancer Biol. 2001;11:277-283.
28. Page K, Uhr J. Mathematical models of cancer dormancy. Leuk Lymphoma. 2005;46:313-327.
29. Meltzer A. Dormancy and breast cancer. J Surg Oncol. 1990;43:181-188.
30. Stewart THM, Hollinshead AC, Raman S. Tumour dormancy: initiation, maintenance and termination in animals and humans. Can J Surg. 1991; 34:321-325.
31. Rice J, Buchan S, Stevenson FK. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J Immunol. 2002;169:3908-3913.
32. Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. JNCI Monogr. 1990;10:61-68.
33. Vuist WMJ, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. Blood. 1994;83:899-906.
34. Hasenkrug KJ, Chesebro B. Immunity to retroviral infection: The Friend virus model. Proc Natl Acad Sci USA. 1997;94:7811-7816.
35. Cesco-Gaspere M, Benvenuti F, Burrone OR. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies. Cancer Immunol Immunother. 2005;54:351-358.
36. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413.
37. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76-79.
38. Freeman GJ, Borriello F, Hodes RJ, et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med. 1993;178:2185-2192.
39. Ostrand-Rosenberg S, Baskar S, Patterson N, et al. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens. 1996;47:414-421.
40. Linsley PS, Greene IL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD 28 and CTLA-4 receptors. Immunity. 1991;1:793-801.
41. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: A costimultory signalling pashway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445-480.
42. Gorelik L, Prokhoova A, Mokyr MB. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th 1 -type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. 1994; 39:117-126.
43. Gorelik L, Rubin M, Prokhorova A, et al. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. J Immunol. 1995;154:3941-3951.
44. Gorelik L, Mokyr MB. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Cancer Immunol Immunother. 1995;41:363-374.
45. Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1995;41:111-121.
46. Lattime EC, Mastrangelo MJ, Bagasra O, et al. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother. 1995; 41:151-156.
47. Lee PP, Zeng D, McCaulay AE, et al. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood. 1997;90:1611-1617.
48. Jovasevic VM, Gorelik L, Bluestone JA, et al. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immunol. 2004;172:1449-1454.
49. O'Garra A, Stapleton G, Dhar V, et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol. 1990;2:821-832.
50. O'Garra A, Chang R, Go N, et al. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol. 1992;22:711-717.
51. Hurwitz AA, Yu TF, Leach DR, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoms. Proc Natl Acad Sci USA. 1998;95:10067-10071.
52. Hurwitz AA, Townsend SE, Yu TF, et al. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcioma. Int J Cancer. 1998;77:107-113.
53. Morecki S, Levi S, Puyesky Y, et al. Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule. Cancer Immunol Immunother. 1995;41:236-242.
54. Morecki S, Lubina-Salomon A, Slavin S, et al. Cytokine gene transduction into non-immunogeneic murine tumor cells. Cytokines Cell Mol Ther. 1998;4:87-94.
55. Paust S, Lu L, McCarty N, et al. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA. 2004;101:10398-10403.
56. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969-1980.
57. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
58. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, et al. CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol. 2001;166:3008-3018.
59. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol. 2002;2:389-400.
60. Misra N, Bayry J, Lacroix-Desmazes S, et al. Cutting edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172:4676-4680.
61. Nicholl M, Lodge A, Brown I, et al. Restored immune response to an MHC-II-restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. J Pediatr Surg. 2004;39:941-946.
62. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother. 2002;25:207-217.